CD24 blockade

CD24 blockade refers to the therapeutic strategy of inhibiting the CD24 protein, a glycosylphosphatidylinositol (GPI)-anchored surface glycoprotein that serves as a critical "don't eat me" signal in the innate immune system. By binding to Siglec-10 on macrophages, CD24 suppresses phagocytosis, allowing tumor cells to evade immune detection. Research indicates that radiotherapy can further upregulate CD24 membrane expression through the ANAPC5/GPAA1 axis, contributing to post-radiation immune evasion. CD24 blockade, typically achieved using monoclonal antibodies, disrupts this interaction, thereby restoring macrophage-mediated tumor cell clearance and enhancing adaptive T-cell responses. This approach is being investigated as a combinatorial treatment with radiotherapy for various solid tumors, including pancreatic, lung, and liver carcinomas.

Other names

anti-CD24 antibodyanti-CD-24 antibodyanti-CD 24 antibodyCD24 inhibitionCD-24 inhibitionCD 24 inhibitionCD24-Siglec-10 blockadeCD-24-Siglec-10 blockadeCD 24-Siglec-10 blockade